Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 3/20 | 0.37 |
| ▸ | TDO2 | P48775 | 3/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | TACR3 | P29371 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29591877 | 1.00 | PDE2A (0.54) | PDE2ACES2CES1MEN1KMT2A | |
| SCHEMBL16861557 | 0.87 | PDE2A (0.44) | PDE2ACES2CES1MEN1KMT2A | |
| SCHEMBL16861556 | 0.87 | PDE2A (0.44) | PDE2ACES2CES1MEN1KMT2A | |
| SCHEMBL31521474 | 0.81 | PDE2A (0.45) | PDE2ACES2CES1MEN1KMT2A | |
| SCHEMBL1008634 | 0.81 | PDE2A (0.39) | PDE2ACES2CES1MEN1KMT2A | |
| SCHEMBL3717829 | 0.77 | PDE2A (0.43) | PDE2ACES2CES1CYP3A4IDO1 | |
| SCHEMBL28221494 | 0.77 | GABRA1 (0.46) | PDE2AMEN1KMT2ACYP3A4ALDH1A1 | |
| SCHEMBL15273670 | 0.76 | PDE2A (0.51) | PDE2ACES2CES1 | |
| SCHEMBL5731352 | 0.76 | CES2 (0.41) | PDE2ACES2CES1MEN1KMT2A | |
| SCHEMBL1349204 | 0.76 | PDE2A (0.65) | PDE2ACES2CES1CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
| WO-2022073469-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-14 | — | — | WO | disclosed |
| EP-3205650-B1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2021-08-04 | — | — | EP | disclosed |
| EP-3205650-B1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2021-08-04 | — | — | EP | disclosed |
| US-10428081-B2 | EGFR inhibitor, preparation method and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2019-10-01 | — | — | US | disclosed |
| US-10428081-B2 | EGFR inhibitor, preparation method and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2019-10-01 | — | — | US | disclosed |
| US-10259820-B2 | EGFR inhibitor, preparation method and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2019-04-16 | — | — | US | disclosed |
| US-10259820-B2 | EGFR inhibitor, preparation method and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2019-04-16 | — | — | US | disclosed |
| US-20190100528-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2019-04-04 | — | — | US | disclosed |
| US-20190100528-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2019-04-04 | — | — | US | disclosed |
| US-20170313714-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170313714-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| EP-3205650-A1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2017-08-16 | — | — | EP | disclosed |
| EP-3205650-A1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016054987-A1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2016-04-14 | — | — | WO | disclosed |
| US-20070142431-A1 | Quinoline 4-carboxamide derivatives and their use as neurokinin 3 (nk-3) receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2007-06-21 | — | — | US | disclosed |
| US-20070142431-A1 | Quinoline 4-carboxamide derivatives and their use as neurokinin 3 (nk-3) receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2007-06-21 | — | — | US | disclosed |
| US-20070142431-A1 | Quinoline 4-carboxamide derivatives and their use as neurokinin 3 (nk-3) receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2007-06-21 | — | — | US | disclosed |
| EP-1651632-A1 | QUINOLINE 4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS NEUROKININ 3 (NK-3) RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005014575-A1 | QUINOLINE 4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS NEUROKININ 3 (NK-3) RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142431-A1 | Quinoline 4-carboxamide derivatives and their use as neurokinin 3 (nk-3) receptor antagonists | TACR3, GRIK3, TACR2 | PDE2A 1226/4885CES2 1473/4885CES1 2501/4885 |
| US-20170313714-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | PDE2A 3895/4885CES2 4381/4885CES1 2572/4885 |
| US-20190100528-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | PDE2A 2971/4885CES2 3934/4885CES1 1991/4885 |
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | PDE2A 2235/4885CES2 796/4885CES1 26/4885 |
| US-10428081-B2 | EGFR inhibitor, preparation method and use thereof | EGFR, ERBB2, ERBB4 | PDE2A 2971/4885CES2 3934/4885CES1 1991/4885 |
| US-10259820-B2 | EGFR inhibitor, preparation method and use thereof | EGFR, ERBB2, ERBB4 | PDE2A 3895/4885CES2 4381/4885CES1 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.